




RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022

MYRIAD GENETICS INC Rank 17 of 50



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

MEDICINAL PRODUCTS & SUBSTANCES 2022

MYRIAD GENETICS INC Rank 17 of 50



The relative strengths and weaknesses of MYRIAD GENETICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MYRIAD GENETICS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 209% points. The greatest weakness of MYRIAD GENETICS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 113%, being 342% points above the market average of -229%.

Input Variable	Value in 1000 USD
Assets Hidden Reserves	0
Assets, Current	484,800
Assets, Non-Current	149,100
General and Administrative Expense	537,800
Goodwill	643,300
Liabilities Hidden Reserves	0
Liabilities, Current	240,100
Liabilities, Non-Current	84,900
Other Assets	0
Other Compr. Net Income	-2,800
Other Expenses	231,500
Other Liabilities	27,900
Other Net Income	133,400
Property, Plant and Equipment, Net	43,500
Research and Development	81,900
Revenues	690,600

Output Variable	Value in 1000 USD
Liabilities	352,900
Assets	1,320,700
Expenses	851,200
Market Value Liabilities	352,900
Market Value Assets	1,320,700
Stockholders Equity	967,800
Net Income	-27,200
Comprehensive Net Income	-28,600
Economic Capital Ratio	113%



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai